Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
Abstract When breast cancer patients start to exhibit resistance to hormonal therapy or chemotherapy, the mTOR inhibitor everolimus can be considered as an alternative therapeutic agent. Everolimus can deregulate the PI3K/AKT/mTOR pathway and affect a range of cellular functions. In some patients, t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2019
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c7eb9d6b994340dfae24eaf48c223d35 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|